ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside
Johannes H. Schulte, Angelika Eggert
Abstract
Abstract Activating mutations of the anaplastic lymphoma kinase (ALK) gene were identified in the pediatric tumor neuroblastoma, in 2008. Rapid translation of this finding into targeted neuroblastoma therapy was facilitated by the availability of ALK inhibitors developed for adult malignancies and an efficient preclinical and clinical research program. See related article by Foster et al., p. 3543
Topics & Concepts
Anaplastic lymphoma kinaseNeuroblastomaMedicineBench to bedsideCancer researchTranslation (biology)CrizotinibGeneOncologyBiologyGeneticsMessenger RNAMedical physicsCell cultureLung cancerMalignant pleural effusionNeuroblastoma Research and TreatmentsCancer therapeutics and mechanismsNeuroendocrine Tumor Research Advances